Rome consensus conference - statement; human papilloma virus diseases in males

BMC Public Health

Carla Maria Zotti⁴  Mauro Picardo¹  Antonio Perino⁹  Saverio G Parisi⁷  Sandra Mazzoli⁶  Luciano Mariani⁵  Carlo Foresta^1,12  Vincenzo Ficarra²  Riccardo Bartoletti³  Vincenzo Gentile⁸  Vincenzo Mirone^1,10  Andrea Lenzi^1,11 

[1]Laboratory of Skin Physiopathology San Gallicano Dermatological Institute IRCCS, Rome, Italy

[2]Department of Urology, University of Padua, Padua, Italy

[3]Department of Urology, Santa Maria Annunziata Hospital, Florence, Italy

[4]Department of Public Health and Microbiology, University of Turin, Turin, Italy

[5]Department of Obstetrics and Gynaecology, Regina Elena National Cancer Institute, Rome, Italy

[6]Centre Responsible, Sexually Transmitted Disease Centre, Santa Maria Annunziata Hospital, Florence, Italy

[7]Department of Histology, Microbiology and Medical Biotechnologies, University of Padua, Padua, Italy

[8]Institute/Department of Urology, La Sapienza University, Rome, Italy

[9]Head of Obstetrics and Gynecology Department, University of Palermo, Palermo, Italy

[10]Institute/Department of Urology, Federico II University, Naples, Italy

[11]Institute/Department of Endocrinology, La Sapienza University, Rome, Italy

[12]Department of Histology, Microbiology and Medical Biotechnologies, Centre for Male Gamete Cryopreservation, University of Padua, Padua, Italy

关键词: Policy;    Consensus conference;    Males;    Vaccination;    HPV-related diseases;   

Others  :  1162562
DOI  :  10.1186/1471-2458-13-117

 received in 2012-02-20, accepted in 2013-01-09,  发布年份 2013

【 摘 要 】

Background

Human Papillomavirus (HPV) is a very resistant, ubiquitous virus that can survive in the environment without a host. The decision to analyse HPV-related diseases in males was due to the broad dissemination of the virus, and, above all, by the need to stress the importance of primary and secondary prevention measures (currently available for women exclusively). The objective of the Consensus Conference was to make evidence-based recommendations that were designed to facilitate the adoption of a standard approach in clinical practice in Italy.

Methods

The Sponsoring Panel put a series of questions to the members of the Scientific Committee who prepared a summary of the currently available information, relevant for each question, after the review and grading of the existing scientific literature. The summaries were presented to a Jury, also called multidisciplinary Consensus Panel, who drafted a series of recommendations.

Results

The prevalence of HPV in males ranges between 1.3–72.9%;. The prevalence curve in males is much higher than that in females and does not tend to decline with age. Women appear to have a higher probability of acquiring HPV genotypes associated with a high oncogenic risk, whereas in males the probability of acquiring low- or high-risk genotypes is similar. The HPV-related diseases that affect males are anogenital warts and cancers of the penis, anus and oropharynx. The quadrivalent vaccine against HPV has proved to be effective in preventing external genital lesions in males aged 16–26 years in 90.4%; (95%; CI: 69.2–98.1) of cases. It has also proved to be effective in preventing precancerous anal lesions in 77.5%; (95%; CI: 39.6–93.3) of cases in a per-protocol analysis and in 91.7%; (95%; CI: 44.6–99.8) of cases in a post-hoc analysis. Early ecological studies demonstrate reduction of genital warts in vaccinated females and some herd immunity in males when vaccine coverage is high, although males who have sex with males gained no benefit at all. Males with an immunodeficiency disease are at greater risk of developing disease. Infertility seems to be caused by HPV in some cases. Studies demonstrate vaccination to both genders can be more efficacious and social equity matters are to be taken into consideration.

Conclusions

The Jury made Recommendations based on the scientific evidence presented by the Scientific Committee. Accordingly, for prevention purposes and social fairness and equality, as both sexes are affected by the disease, the vaccination of 12-year-old males against HPV should be recommended in order to guaranty protection to everyone. Aspects related to healthcare policy and economic sustainability, are to be discussed by respective public system representatives. More campaigns to raise awareness through all institutional channels are needed, not only regarding anogenital warts, but for HPV-related diseases in general in males in accordance to new scientific evidences.

【 授权许可】

   
2013 Lenzi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Koutsky L, Galloway DA, Holmes KK: Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988, 10:122-163.
• [2]Gavillon N, Vervaet H, Derniaux E, Terrosi P, Graesslin O, Quereux C: How did I contract human Papillomavirus (HPV)? Gynecol Obstet Fertil 2010, 38(3):199-204.
• [3]Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR: Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006, 194(8):1044-1057.
• [4]Partridge JM, Koutsky LA: Genital human papillomavirus infection in men. Lancet Infect Dis 2006, 6(1):21-31.
• [5]Harbour R, Miller J: A new system for grading recommendations in evidence based guidelines. BMJ 2001, 323:334-336.
• [6]Giuliano AR, Lazcano E, Villa LL, Flores R, Salmeron J, Lee JH, Papenfuss MR, Abrahamsen M, Jolles E, Nielson CM, Baggio ML, Silva R, Quiteri M: The Human Papillomavirus Infection in Men (HIM) study: HPV prevalence and type-distribution among men residing in Brazil, Mexico, and the US. Cancer Epidemiol Biomarkers Prev 2008, 17(8):2036-2043.
• [7]Giuliano AR, Nielson CM, Flores R, Dunne EF, Abrahamsen M, Papenfuss MR, et al.: The optimal anatomic sites for sampling heterosexual men for human Papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis 2007, 196(8):1146-1152.
• [8]Hippelainen M, Syrjanen S, Hippelainen M, et al.: Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transm Dis 1993, 20:321-328.
• [9]Weaver BA, Feng Q, Holmes KK, Kiviat N, Lee SK, Meyer C, et al.: Evaluation of genital sites and sampling techniques for detection of human Papillomavirus DNA in men. J Infect Dis 2004, 189(4):677-685.
• [10]Lazcano-Ponce E, Herrero R, Munoz N, et al.: High prevalence of human papillomavirus infection in Mexican males: comparative study of penile-urethral swabs and urine samples. Sex Transm Dis 2001, 28:277-280.
• [11]Kjaer SK, Munk C, Winther JF, Jorgensen HO, Meijer CJ, van den Brule AJ: Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 2005, 14:1528-1533.
• [12]Lajous M, Mueller N, Cruz-Valdez A, Aguilar LV, Franceschi S, Hernandez-Avila M: Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 2005, 14:1710-1716.
• [13]Shin H-R, Franceschi S, Vaccarella S, et al.: Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004, 190:468-476.
• [14]Wikstrom A, Popescu C, Forslund O: Asymptomatic penile HPV infection: a prospective study. Int J STD AIDS 2000, 11:80-84.
• [15]Svare EI, Kjaer SK, Worm AM, Osterlind A, Meijer CJ, van den Brule AJ: Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sex Transm Infect 2002, 78:215-218.
• [16]Baldwin SB, Wallace DR, Papenfuss MR, et al.: Human Papillomavirus infection in men attending a sexually transmitted disease clinic. J Infect Dis 2003, 187:1064-1070.
• [17]Van Doornum GJ, Prins M, Juffermans LH, et al.: Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple sexual partners: a prospective study. Genitourin Med 1994, 70:240-246.
• [18]Takahashi S, Takeyama K, Miyamoto S, et al.: Incidence of sexually transmitted infections in asymptomatic healthy young Japanese men. J Infect Chemother 2005, 21:76-82.
• [19]Bleeker MC, Hogewoning CJ, Van Den Brule AJ, et al.: Penile lesions and human Papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. J Am Acad Dermatol 2002, 47:351-357.
• [20]Franceschi S, Castellsagué X, Dal Maso L, et al.: Prevalence and determinants of human Papillomavirus genital infection in men. Br J Cancer 2002, 86:705-711.
• [21]Bleeker MC, Hogewoning CJ, Berkhof J, et al.: Concordance of specific human Papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis 2005, 41:612-620.
• [22]Hippelainen MI, Yliskoski M, Syrjanen S, et al.: Low concordance of genital human Papillomavirus (HPV) lesions and viral types in HPV infected women and their male sexual partners. Sex Transm Dis 1994, 21:76-82.
• [23]Nicolau SM, Camargo CG, Stavale JN, et al.: Human papillomavirus DNA detection in male sexual partners of women with genital human Papillomavirus infection. Urology 2005, 65:251-255.
• [24]Burchell AN, Winer RL, de Sanjosé S, Franco EL: Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006, 24(S3):S52-S61.
• [25]Ronco G, Ghisetti V, Segnan N, Snijders PJF, Gillio-Tos A, Meijer CJ, Merletti F, Franceschi S: Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer 2005, 41(2):297-305.
• [26]Franco EL, Villa LL, Sobrinho JP, et al.: Epidemiology of acquisition and clearance of cervical human Papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999, 180:1415-1423.
• [27]Partridge JM, Hughes JP, Feng Q, et al.: Genital human Papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007, 196:1128-1136.
• [28]Suligoi B, Salfa MC, Mariani L: Epidemiologia e management dei pazienti con condilomi genitali in Italia. Ig Sanita Pubbl 2010, 66:733-756.
• [29]Vittori G, Matteolli A, Boselli F, Naldi L, Emberti GL: A new approach to estimate Genital Warts incidence and prevalence in the Italian general female population. It J Gynaecol Obstet 2008, 20(1):33-42.
• [30]Foresta C, Ferlin A, Bertoldo A, Patassini C, Zuccarello D, Garolla A: Human papilloma virus in the sperm cryobank: an emerging problem? Int J Androl 2010, 34:242-246.
• [31]Giovannelli L, Migliore MC, Capra G, Caleca MP, Bellavia C, Perino A, Viviano E, Matranga D, Ammatuna P: Penile, urethral, and seminal sampling for diagnosis of human Papillomavirus infection in men. J Clin Microbiol 2007, 45:248-251.
• [32]Shigehara K, Sasagawa T, Kawaguchi S, Kobori Y, Nakashima T, Shimamura M, Taya T, Furubayashi K, Namiki M: Prevalence of human Papillomavirus infection in the urinary tract of men with urethritis. Int J Urol 2010, 17:563-569.
• [33]Ogilvie GS, Taylor DL, Achen M, Cook D, Krajden M: Self-collection of genital human Papillomavirus specimens in heterosexual men. Sex Transm Infect 2009, 85:221-225.
• [34]Barzon L, Militello V, Pagni S, et al.: Distribution of human Papillomavirus types in the anogenital tract of females and males. J Med Virol 2010, 82:1424-1430.
• [35]Rintala MA, Grénman SE, Pöllänen PP, Suominen JJ, Syrjänen SM: Detection of high-risk HPV DNA in semen and its association with the quality of semen. Int J STD AIDS 2004, 15:740-743.
• [36]Lai YM, Lee JF, Huang HY, Soong YK, Yang FP, Pao CC: The effect of human Papillomavirus infection on sperm cell motility. Fertil Steril 1997, 67:1152-1155.
• [37]Olatunbosun O, Deneer H, Pierson R: Human Papillomavirus DNA detection in sperm using polymerase chain reaction. Obstet Gynecol 2001, 97:357-360.
• [38]Spandorfer SD, Bongiovanni AM, Fasioulotis S, Rosenwaks Z, Ledger WJ, Witkin SS: Prevalence of cervical human papillomavirus in women undergoing in vitro fertilization and association with outcome. Fertil Steril 2006, 86(3):765-767.
• [39]Nyitray AG, Smith D, Villa L, et al.: Prevalence of and risk factors for anal human Papillomavirus infection in men who have sex with women: a cross-national study. J Infect Dis 2010, 201(10):1498-1508.
• [40]Palefsky JM: Human Papillomavirus-related disease in men: not just a women’s issue. J Adolesc Health 2010, 46(Suppl 4):S12-S19.
• [41]Giraldo PC, Eleutério J Jr, Cavalcante DI, Gonçalves AK, Romão JA, Eleutério RM: The role of high-risk HPV-DNA testing in the male sexual partners of women with HPV-induced lesions. Eur J Obstet Gynecol Reprod Biol 2008, 137:88-91.
• [42]Molijn A, Kleter B, Quint W, van Doorn LJ: Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005, 32(Suppl 1):S43-S51.
• [43]Smith JS, Backes DM, Hudgens MG, Bailey RC, Veronesi G, Bogaarts M, Agot K, Ndinya-Achola JO, Maclean I, Agingu W, Meijer CJ, Moses S, Snijders PJ: Prevalence and risk factors of human papillomavirus infection by penile site in uncircumcised Kenyan men. Int J Cancer 2010, 126:572-577.
• [44]Damay A, Fabre J, Costes V, Didelot JM, Didelot MN, Boulle N, Segondy M: Human Papillomavirus (HPV) prevalence and type distribution, and HPV-associated cytological abnormalities in anal specimens from men infected with HIV who have sex with men. J Med Virol 2010, 82:592-596.
• [45]Trottier H, Burchell AN: Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 2009, 12:291-307.
• [46]Tanzi E, Amendola A, Bianchi S, Fasolo MM, Beretta R, Pariani E, Zappa A, Frati E, Orlando G: Human Papillomavirus genotypes and phylogenetic analysis of HPV-16 variants in HIV-1 infected subjects in Italy. Vaccine 2009, 27(Suppl 1):A17-A23.
• [47]Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener HG, Herbert A, Daniel J, von Karsa L: European guidelines for quality assurance in cervical cancer screening. 2nd edition. IARC; 2008. The full text is available for download from the IARC’s web site: http://screening.iarc.fr/doc/ND7007117ENC_002.pdf webcite
• [48]Barzon L, Giorgi C, Buonaguro FM, Palù G, the Italian Society for Virology: Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Canc 2008, 3:14. The full text is available for download from: http://www.infectagentscancer.com/content/pdf/1750-9378-3-14.pdf webcite BioMed Central Full Text
• [49]Winer RL, Lee SK, Hughes JP, et al.: Genital human papillomavirus infection: incidence and risk factors in a cohor of female university students. Am J Epidemiol 2003, 157:218-226.
• [50]Benevolo M, Mottolese M, Marandino F, et al.: HPV prevalence among healthy italian male sexual partners of women with cervical HPV-infection. J Med Virol 2008, 80:1275-1281.
• [51]Burchell AN, Tellier PP, Hanley J, Coutlée F, Franco EL: Human Papillomavirus infections among couples in new sexual relationships. Epidemiology 2010, 21(1):31-37.
• [52]Goedert JJ, Cote TR, Virgo P, et al.: Spectrum of AIDS-associated malignant disorders. Lancet 1998, 89:201-211.
• [53]Bosch FX, Castellsagué X, Munoz N, et al.: Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancers in Spain. J Natl Cancer Inst 1996, 88:1060-1067.
• [54]Kjaer SK, Chackerian B, van den Brule AJ, et al.: High-risk human papillomavirus is sexually transmitted: evidence from a follow up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001, 10:101-106.
• [55]Penn I: Cancer in the immunosuppressed organ recipient. Transplant Proc 1991, 23:1771-1772.
• [56]Serraino D, Dal Maso L, La Vecchia C, Franceschi S: Invasive cervical cancer as an AIDS-defining illness in Europe. AIDS 2002, 16:781-786.
• [57]Auvert B, Lissouba P, Cutler E, Zarca K, Puren A, Taljaard D: Association of oncogenic and nononcogenic human papillomavirus with HIV incidence. J Acquir Immune Defic Syndr 2010, 53(1):111-116.
• [58]CDC: Sexually transmitted diseases treatment guidelines. MMWR 2006, 55:1-94. RR-11
• [59]Future II Study Group: Quadrivalent vaccine against human Papillomavirus to prevent highgrade cervical lesions. N Engl J Med 2007, 356(19):1915-1927.
• [60]Ault KA: Effect of prophylactic human Papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369:1861-1868.
• [61]Kjaer SK, Sigurdsson K, Iversen OE, et al.: A pooled analysis of continued prophylactic efficacy of quadrivalent human Papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Canc Prev Res 2009, 2(10):868-878.
• [62]Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group: Efficacy of human Papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-323.
• [63]Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human Papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
• [64]Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulvar and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369:1693-1702.
• [65]The Future I/II Study Group: Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 340:c3493.
• [66]Muñoz N, Manalastas R Jr, Pitisuttithum P, et al.: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 2009, 373:1949-1957.
• [67]Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D: Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011, 364:401-411.
• [68]Maden C, Sherman KJ, Beckmann AM, Hislop TG, Teh CZ, Ashley RL, et al.: History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993, 85:19-24.
• [69]European Commission, Directorate General for Health and Consumers, Public Health: Gardasil, summary of product characteristics. Full text available for download from the European Commission’s web site: http://ec.europa.eu/health/documents/community-register/2011/20110801107489/anx_107489_en.pdf webcite
• [70]Centers for Disease Control and Prevention (CDC): Morbidity and Mortality Weekly Report (MMWR). FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV 4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP) 2010, 59(20):630-632. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm?s_cid=mm5920a5_e webcite
• [71]Palefsky J: Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men. 26th International Papillomavirus Conference (IPC). Montréal, Canada; 2010. Abstract available for download from the IPC’s web site: http://hpv2010.org/main/images/stories/hpv2010_abstracts.pdf webcite
• [72]Goldstone S: A case assignment methodology for determining qHPV vaccine efficacy against anal intraepithelial neoplasia. 26th International Papillomavirus Conference (IPC). Montréal, Canada; 2010. Abstract (P-597) available for download from the IPC’s web site: http://hpv2010.org/main/images/stories/hpv2010_abstracts.pdf webcite
• [73]Food and Drug Administration (FDA): FDA news release. Gardasil approved to prevent anal cancer. Full text available for download from the FDA’s web site: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237941.htm webcite
• [74]Hogewoning CJ, Bleeker MC, van den Brule AJ, et al.: Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human Papillomavirus: a randomized clinical trial. Int J Cancer 2003, 107:811-816.
• [75]Nielson CM, Harris RB, Dunne EF, Abrahamsen M, Papenfuss MR, Flores R, Markowitz LE, Giuliano AR: Risk factors for anogenital human Papillomavirus infection in men. J Infect Dis 2007, 196:1137-1145.
• [76]Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS: Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009, 85:499-502.
• [77]Chesson H: Overview of cost-effectiveness of male HPV vaccination. Centers for Disease Control (CDC) and Prevention Advisory Committee on Immunization Practices; 2009. Full text available for download from the CDC’s web site: http://www.cdc.gov/vaccines/recs/acip/downloads/min-oct09.pdf webcite
• [78]Markowitz L: Quadrivalent HPV vaccine for males: future considerations. Centers for Disease Control (CDC) and Prevention Advisory Committee on Immunization Practices; 2010. Full text available for download from the CDC’s web site: http://www.cdc.gov/vaccines/recs/acip/downloads/min-feb10.pdf webcite
• [79]Garnett GP, Kim JJ, French K, Goldie SJ: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006, 24(suppl 3 S3/):178-186.
• [80]Udesky L: Push to mandate HPV vaccine triggers backlash in USA. Lancet 2007, 369:979-980. CrossRef][Web of Science][Medline]
• [81]Robertson SE, Cutts FT, Samuel R, Diaz-Ortega JL: Control of rubella and congenital rubella syndrome (CRS) in developing countries. Part 2: vaccination against rubella. Bull World Health Organ 1997, 75:69-80.
• [82]Giambi C, National Institute of Health - Istituto Superiore di Sanità. CNEPS, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute: Ricognizione delle decisioni regionali in merito alla vaccinazione anti-HPV e primi dati di copertura vaccinale a fine anno. 2009. Full text available for download from the NIH’s web site: http://www.epicentro.iss.it/focus/hpv/pdf/HPV-2009.pdf webcite